Replies to post #7884 on Ariad Pharmaceuticals Inc fka ARIA

[bladerunner1717]

Thanks, eawolfie. I get Kipster's point, but I'm sorry, I don't buy the argument. I guess reasonable people can disagree about this.

On a slightly different note, I'm wondering if NICE's ruling will stand. I'm sure the hematologists in England are not happy about this ruling, nor the patients who are refractory to Glivec.


Bladerunner

[bellweather1]

I believe I understand what you're saying.

However, now it seems we have a situation where, though pona will tie up all the mutations(as it always would have), it can't derive any addition market benefit by moving to first line in the UK for use in cml generally.

Before this, it would have retained that(1stline) potential as well(the potential of being reimbursed at a higher rate for even a small benefit increase).

Now, apparently, no one gets that, and the generic rate structure in non-mutation cml rules the day.

With the advent of mutation testing, I think any previous advantage the other meds might have gotten (in terms of being tried first) was probably off the table already.